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Abstract Remote ischaemic conditioning (rIC) has
demonstrated its effectiveness as a powerful cardioprotec-
tive tool in number of preclinical and limited clinical set-
tings. More recently, ischaemic postconditioning given
after an ischaemic event such as a myocardial infarction
(MI) has shown not only to reduce infarct size but also to
have beneficial effects on acute remodelling post-MI and to
reduce the burden of heart failure and other detrimental
outcomes. Building on this platform, repeated rIC over a
number of days has the potential to augment the protective
process even further. This review considers the current
evidence base from which the concept of rIC in the setting
of post-MI remodelling has grown. It also discusses the
ongoing and planned clinical trials which are attempting to
elucidate whether the protection imparted by rIC in the
preclinical setting can be translated to the clinic and
become a realistic weapon in the clinician’s armoury to
tackle acute remodelling and heart failure post-MI.
Keywords Cardioprotection  Heart failure 
Remodelling  Myocardial infarction  Remote ischaemic
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Introduction
Remote ischaemic conditioning (rIC) is a non-invasive
therapeutic technique whereby intermittent interruption of
blood to an organ or muscle confers protection against
ischaemia/reperfusion (I/R) injury to a distant organ. RIC
can be implemented prior to an expected ischaemic insult
(preconditioning), during the evolution of an ischaemic
insult (per-conditioning) or soon after the completion of an
ischaemic insult (postconditioning). For the purposes of this
review, the term rIC will encompass all of these techniques.
The technique evolved from the phenomenon of local
ischaemic conditioning of the heart and has been success-
fully used to reduce myocardial damage and improve car-
diovascular outcomes in the context of primary
percutaneous intervention (PPCI) for acute myocardial
infarction (MI) [1, 2], elective coronary angioplasty [3–5],
coronary artery bypass surgery [6], valve surgery [7] and
paediatric cardiac surgery [8]. Beyond the well-established
acute protective phase, early preclinical studies have hinted
at an additional role for rIC, predominantly in positively
influencing post-MI ventricular remodelling. In addition to
directly affecting final infarct size, rIC may act to increase
recruitment of stunned myocardium as well as modulating
remodelling processes such as cell death with an increased
emphasis on autophagy, cardiomyocyte hypertrophy,
extracellular matrix (ECM) changes and the influx of pro-
inflammatory cells to the damaged myocardium. This
potential new role for rIC may have a profound effect in
reducing the incidence and impact of post-MI heart failure.
Remodelling following myocardial infarction
Heart failure is a major cause of long-term mortality and
morbidity after MI. Analysis of registries and of large
clinical trials across the western world, conducted in the
era of acute revascularisation, has reported incidence rates
of post-MI heart failure ranging from 10 to 50 %,
depending on a number of factors including the degree and
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location of infarcted myocardium, how MI and heart failure
were defined, whether there was pre-existing heart failure,
the treatment modalities used and the characteristics of the
populations analysed [9]. A retrospective analysis of
Framingham Heart Study participants demonstrated an
increase in the incidence of post-MI heart failure from the
1970s to the 1990s, closely linked to a decrease in mor-
tality in acute MI, likely due to advances in myocardial
salvage over this time period [10].
The development of chronic heart failure following MI
most commonly results from adverse remodelling of the left
ventricle, a process of structural reorganisation which occurs
within the first few weeks to months after the acute event.
Such remodelling is directly related to the extent of
myocardial damage (due to initial necrosis and secondary
apoptosis) and is most likely to occur following transmural
infarction, as well as being heavily influenced by concomi-
tant microvascular obstruction and lethal reperfusion injury
in the era of acute revascularisation [11, 12]. The process of
remodelling is triggered by the initial ischaemia/reperfusion
insult which sets intomotion a number of events. In the initial
stages, the changes in the left ventricle are predominantly
due to the effects of infarct expansion causing cardiomy-
ocyte necrosis and apoptosis which ultimately leads to
myocardial wall dilatation via a number of mechanisms
including changes in excitation–contraction coupling and an
increased expression of foetal genes leading to an alteration
in proteins produced. In the later stages, remodelling is lar-
gely fuelled by hypertrophy of surviving cardiomyocytes in
response to pressure and volume changes and neurohumoral
signalling, reorganisation of the ECMwith deposition of scar
tissue and an inflammatory-driven process whereby sub-
stantial ECM turnover in border areas leads to cell slippage
and further dilatation. Fromawhole-organ perspective, these
changes impact on cardiac dimensions and function. These
initial changes act to maintain an adequate cardiac output in
the face of a loss of functioning myocardium; however, over
time remodelling becomes maladaptive. Indeed the extent
and the nature of remodelling (both compensatory and sub-
sequently maladaptive), and its progression is a powerful
predictor for both heart failure and death following MI, as
well as having prognostic implications for further MI, stroke
and cardiac arrest [13, 14]. Preventing or modifying some or
all of the drivers for remodelling may go some way to
reducing major adverse cardiovascular events in this setting.
Local ischaemic conditioning
In 1986, Murry et al. [15] first described an endogenous
cardioprotective mechanism in a canine model of MI ter-
med ischaemic preconditioning (IPC), whereby intermit-
tent, non-lethal occlusion and reperfusion of the left
anterior descending artery (LAD) immediately prior to a
period of sustained occlusion significantly reduced the final
infarct size. The first in vivo study in humans assessing the
effect of preconditioning was performed by Deutsch et al.
[16]. In a small group of patients undergoing elective PCI
for an obstructed (LAD), they showed a reduction in
electrographic, metabolic and clinical markers of ischae-
mia during the second cycle of balloon inflation compared
to the first. Yellon et al. [17] later utilised IPC prior to
coronary artery bypass grafting surgery (CABG), demon-
strating preserved levels of myocardial adenosine triphos-
phate during cardiopulmonary bypass. Over the intervening
years, evolution of this technique has seen it applied to
situations of unpredictable cardiac ischaemia (as opposed
to anticipated ischaemia from elective surgery). Zhao et al.
[18] in 2003 introduced the concept of ischaemic post-
conditioning (IPostC) whereby the conditioning stimulus is
applied immediately or soon after the index ischaemic
event by intermittent inflations and deflations of the intra-
coronary balloon to stagger reperfusion. Using a canine
model, they demonstrated the effectiveness of IPostC in the
context of acute MI with comparable levels in infract size
reduction and levels of tissue oedema as well as a variety of
markers of cardiac damage when compared to IPC. The
possible clinical applicability of IPostC in the setting of
acute coronary events was quickly realised. By staggering
reperfusion during PCI by repetitively inflating and
deflating the angioplasty balloon in the culprit vessel for
short periods of time, Laskey et al. [19] showed a reduction
in final electrocardiographic ST-segment elevation size and
an increase in distal myocardial perfusion. Staat et al. [20],
using a similar technique at the time of PCI, showed a
significant reduction in creatine kinase release and an
increase in myocardial reperfusion in the conditioned
group.
Windows of protection and delayed conditioning
Two distinct phases of cardioprotection resulting from
ischaemic preconditioning have been shown to exist and
are commonly termed ‘windows of protection’ [21]. The
first window begins immediately following the condition-
ing stimulus and lasts up to 4 h. Protection within this time
period is mainly induced through posttranslational modi-
fication of proteins. The second or delayed window of
protection occurs 12–72 h after the conditioning event and
confers protection mainly through gene transcriptional
changes [22–24].
In the context of protection against the long-term effects
of I/R and subsequent remodelling, the timing of the con-
ditioning stimulus is paramount. Early studies suggested
that to impart meaningful protection, conditioning must be
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implemented before, during or immediately after the clin-
ical event as reperfusion injury is thought to occur within
the first 15 min after the event. Dispelling this belief
somewhat, Roubille et al. [25] described the damage
associated with reperfusion as a ‘wave front’ and showed
that rIC after I/R can be effective up to 30 min post-MI.
Basalay et al. [26] also found a similar but more modest
phenomenon in a rat model of I/R where rIC was effective
in reducing injury when started up to 10 min into reper-
fusion time. The ability to impart protection, even after a
significant time after the acute event, may prove clinically
useful in the context of protection against adverse remod-
elling in post-MI in patients presenting late to hospital, as
the remodelling process continues to evolve for several
days after the initial insult.
Proposed mechanisms of remote ischaemic
conditioning
RIC took the concept of IPC a step further, allowing the
conditioning stimulus to be applied away from the heart in
a distant tissue bed. Przyklenk et al. [27] were the first to
demonstrate rIC in an animal model of ischaemia/reper-
fusion. By preconditioning the left circumflex coronary
(LCx) artery in dogs, they were able to protect the remote
myocardium supplied by the LAD following transient
ligation to induce MI and reperfusion. Kerendi et al. [28]
later demonstrated the cardioprotective effects of rIC in the
post-MI setting. After 30 min of coronary artery occlusion
in rat hearts, they remotely conditioned the kidneys, then
reperfused the heart and showed a 50 % decrease in infarct
size compared to the control.
In humans, the most practical application of rIC is by
sequentially inflating a blood pressure cuff on the arm or
leg, commonly using 3–4 cycles of inflation and deflation.
This non-invasive technique affords protection not only to
the heart but also to a number of other organs, most notably
the brain and kidneys (for review, see Ref. [29]). Although
the exact mechanisms of signal transduction from the tis-
sue/organ undergoing rIC to the target organ have yet to be
elucidated, various authors have highlighted the impor-
tance of humoral and neural signalling pathways as well as
modulation of the systemic inflammatory response, perhaps
working in an interdependent manner [30, 31].
The humoral signalling theory postulates that blood-
borne factors are released locally by the tissue undergoing
rIC and are then relayed in the blood to the target organ,
where they bind to G-protein-coupled receptors triggering
a number of intracellular signalling pathways. A number of
research groups have illustrated the importance of humoral
signalling by isolating naı¨ve animal hearts and treating
them with superfusate from rIC-treated animals or human
donors and demonstrating cardioprotection [32, 33]. We
have shown this in our laboratory using isolated adult rat
cardiomyocytes [34]. Over the years, numerous humoral
factors have been implicated including adenosine, brady-
kinin, nitrate/nitrites, opioid peptides, prostaglandins,
natriuretic peptides, endocannabinoids, angiotensin I and
calcitonin gene-related peptide. It is currently believed that
the signalling factor(s) is between 3.5 and 15 kDa in size
and is hydrophobic [35, 36]. More recent candidates for the
responsible humoral messenger include stromal cell-
derived factor-1 (SDF-1a) which recruits stem cells and is
activated by hypoxia [37], circulating extracellular vesicles
[38] and a panel of anti-inflammatory proteins including
haptoglobin and transthyretin [39].
The first evidence for the involvement of neural sig-
nalling in rIC was given by Gho et al. [40]. By adminis-
tering intravenous hexamethonium (a ganglion blocker),
they abolished protection afforded by remote ischaemic
preconditioning of anterior mesenteric artery or renal
artery against sustained MI. Subsequent experiments by
Ding et al. [41] showed that by directly severing the renal
nerve, one could abolish the cardioprotective effect of renal
ischaemia rIC in rabbits. Mastitskaya et al. [42] proposed
that rIC involves transmission via vagal preganglionic
neurones, whilst further studies have advocated C-fibres as
the sensory neural mechanism responsible for rIC [43].
Indeed there is some suggestion that a combined humoral/
neural signalling relay exists where adenosine (or other
candidate factors) acts via modulation of afferent neural
pathway [44]. Jensen et al. [45] demonstrated that the
dialysates from type 2 diabetic individuals with peripheral
neuropathy did not afford protection against infarction in a
rabbit model, whereas the dialysate from non-diabetics and
diabetics without peripheral neuropathy did, implying a
fundamental role for neuronal signalling in this process.
Furthermore, Basalay et al. [26] suggested that rIC in the
pre-, per- and immediate post-MI period is heavily
dependent on sympathetic messaging, whereas delayed
remote ischaemic postconditioning i.e.[10 min after the
event, appears not to rely so heavily on this neural sig-
nalling. This suggests a greater level of importance for
humoral signalling in late postconditioning as well as
potentially for repeated rIC.
A final hypothesised mechanism of rIC signalling
involves modulation of the inflammatory response,
important in initiating and controlling wound healing.
Cheung et al. [8] demonstrated that patients given a rIC
stimulus prior to undergoing open-heart surgery had a
reduced systemic inflammatory response and reduced
levels of cardiac damage. Li et al. [46] also highlighted the
importance of inflammation by demonstrating a blunted
cardioprotective response in mice deficient in NFjB (a
transcription factor involved in most inflammatory
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processes) subjected to rIC. The importance of NFjB was
underlined by Wei et al. [47] in a rat model of repeated rIC
and MI where they demonstrated significantly reduction in
phosphorylation of the NFjB subunit p65 and its inhibitory
protein IjBa. In addition, this study showed a reduction in
the infiltration of macrophages and neutrophils into the
infarcted tissue in the rIC groups as well as a reduction in
monocyte chemotactic protein 1 (MCP-1) in the border
zone of infarcted tissue. More recently, Cai et al. [48] have
shown up-regulation of expression of interleukin-10 (a
potent anti-inflammatory cytokine) in a mouse model of
rIC which leads to a reduction in myocardial infarct size
and improved cardiac contractility.
Although some mystery still exists as to the mechanisms
of rIC signalling, once the signal reaches the intended
organ, the downstream intracellular pathways of rIC are
thought to share much in common with local ischaemic
conditioning. A number of intracellular pathways have
been implicated including the reperfusion injury signalling
kinase (RISK) pathway, involving ERK 1/2, p38 MAPK,
PI3K-AKT and GSK3b, acting ultimately to prevent
opening of the mitochondrial permeability transition pore
(mPTP) at the time of reperfusion. Another important
downstream pathway is the survivor activating factor
enhancement (SAFE) pathway, involving activation of the
JAK-STAT3/5 axis, a protective transcription factor in the
context of acute ischaemia (for a detailed review, see Ref.
[49]). The first window of protection is thought to depend
heavily on the RISK pathway, nitric oxide (NOS), PKCe,
PKCc and reactive oxygen species. The second window of
protection is more dependent on the SAFE pathway and
inducible nitric oxide (iNOS) as well as retaining a sig-
nificant overlap with some of the pathways implicated in
the first window of protection [21, 50]. For a detailed
discussion of our current understanding of the mechanisms
of rIC, see the proceedings from the most recent Biennial
Hatter Cardiovascular Institute Workshop [51].
Remote ischaemic conditioning and acute
myocardial infarction
The simple and safe technique of inducing ischaemia by
inflating a blood pressure cuff applied to the forearm to a
level greater than the systolic blood pressure was first used
in the setting of acute MI by Bøtker et al. [1] in the CONDI
trial. In this landmark study 4 9 5-min cycles of blood
pressure cuff inflation/deflation were applied to the forearm
of a cohort of ST-segment elevation MI (STEMI) patients
in the ambulance on-route to PPCI and showed that with
large anterior MIs caused by total occlusion of the LAD,
conditioned patients had a significantly better myocardial
salvage index as assessed by gated single-photon emission
CT (SPECT) than the control group. A smaller study by
Rentoukas et al. [2] was undertaken in STEMI patients
where rIC was applied just after PCI using 4 9 4-min
cycles of a forearm blood pressure cuff inflation/deflation
in combination with morphine. There was a significant
reduction in troponin T levels in the conditioned group
compared to the control group as well as ST-segment
deviation resolution. More recent work by White and col-
leagues further demonstrated the benefits of rIC, imple-
mented in this setting just prior to PPCI in the context of
STEMI. They showed a reduction in myocardial oedema
and infarct size as measured by cardiac magnetic resonance
imaging (cMRI) as well as reduced levels of troponins in
the conditioned group [52]. The excitement generated by
these trials must be tempered by the difficulty in inter-
preting individual studies with small sample sizes and
significant population heterogeneity which often assesses
non-clinical outcome measures. Reassuringly, a recent
comprehensive systematic review and meta-analysis of the
available trial data by Le Page et al. [53] showed signifi-
cant reductions in the hard end points of MACCE and all-
cause mortality in conditioned groups compared to controls
in this setting.
Remote ischaemic conditioning and remodelling
postmyocardial infarction
Thibault et al. first hinted at the prospect that the effects of
local IPostC after an MI may have a positive influence on
myocardial contractility [54]. They demonstrated a 7 %
greater left ventricular ejection fraction (LVEF) after
1 year compared with the control group (p = 0.04) [55].
Similarly, Munk et al. [54] in a sub-study of the CONDI
trial showed that in MI patients with an area at risk (AAR)
of over 35 %, those who received rIC immediately prior to
PPCI had significant improvement in LVEF after 30 days
compared to the control group (51 ± 11 vs. 46 ± 9 %,
p = 0.03). Furthermore, Hoole et al. [5], as well as
demonstrating reduced levels of Troponin T in patients
undergoing elective PCI who received rIC compared to
control, showed that at 6 months, the major adverse cardiac
and cerebral event rate (MACCE) was lower in the rIC
group (4 vs. 13 events, p = 0.018). More recent data
published by the CONDI investigators underlined some of
the long-term benefits of rIC [56]. They followed 256
patients who had suffered a STEMI to a median of
3.8 years, split equally between those who had received
rIC at the time of PPCI and those who had received PPCI
only. MACCE occurred in 13.5 % of the intervention
group compared to 25.6 % of the control group (HR 0.49,
CI 0.27–0.89, p = 0.018). However, due to the small
sample size, no solid inferences could be made about a
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number of secondary outcome measures, including the
development of chronic heart failure.
In all these studies, one-off rIC at or around the time of
MI has pointed towards the potential for this technique to
reduce the incidence chronic heart failure. However, the
degree to which the difference in LVEF and other markers
of heart failure is due to remodelling, as opposed to
attenuation of infarct size around the time of the acute
event, is difficult to ascertain. Animal studies by Red-
dington’s group have hinted that the progression to heart
failure can be strongly attenuated, in a ‘dose-dependent
manner’, by serial bouts of rIC soon after an ischaemic
event. In a rat model of acute MI, Wei et al. [47] demon-
strated the greatest improvement in LV chamber size, LV
function and haemodynamic changes post-MI in the group
that received repeated remote conditioning every day for
28 days compared to a control group and two groups
receiving one-off applications of rIC either before or dur-
ing ischaemia. The benefit appears to be in addition to the
initial improvement seen due to reduction in infarct size
and points towards novel mechanism of cardioprotection
acting directly on remodelling. The study highlighted a
variety of ways in which repeated rIC may work in this
context including a reduction in oxidative stress, attenua-
tion of the expression of genes associated with fibrosis and
hypertrophy, and blunting of the inflammatory response
with reduced levels of neutrophil and macrophage infil-
tration in the myocardium and reduced cytokine signalling.
Previously, the same group had demonstrated that repeti-
tive rIC significantly altered the behaviour of neutrophils
after MI with reduced levels of adhesion at days 1 and 10
as well as a reduction in phagocytosis at day 10, apoptosis
at days 1 and 10 and an overall change in the prolife of
cytokine release [57]. More recent work from this group
has suggested the existence of separate and very distinct
mechanisms by which ‘one-off’ traditional rIC and repe-
ated rIC infer protection. Whilst traditional rIC acts
through the pathways described previously, repeated rIC
was shown in this study to increased production of the
autophagosome proteins LC3-II, cathepsin-L and Atg5
[58]. Yamaguchi et al. reinforced the power of repeated rIC
post-MI and implicated exosomes as the mediators for
signalling in rIC, possibly by their action of transferring
anti-fibrotic microRNAs such as miR29a as well as IGF-1,
which is known to be protective in the context of remod-
elling [59]. In addition, work by our laboratory showed that
superfusate taken from ischaemic-conditioned Langendorff
perfused rat hearts as well as serum taken from human
volunteers immediately after undergoing rIC stimulation
both independently inhibited endothelin-1-induced hyper-
trophy in a cellular model of hypertrophy alluding to a
humoral mechanism of action [60].
Future perspectives
Multiple studies are underway to assess the impact of one-
off rIC protocols at the time of MI on various heart failure-
related outcome. Following on from the first CONDI study
[56], CONDI-2 (Effect of RIC on Clinical Outcomes in
STEMI Patients Undergoing PPCI) is well underway. This
study aims to recruit 2300 participants over a 36-months
period from a number of sites across Europe (http://www.
clinicaltrials.gov/ct2/show/NCT01857414) with the pri-
mary outcome of assessing cardiovascular mortality and
hospitalisation for heart failure at 1 year. Completion of
the study is expected in late 2016. Running in collaboration
with the CONDI-2 trial is the ERIC-PPCI (Effect of
Remote Ischaemic Conditioning on clinical outcomes in
ST-segment elevation myocardial infarction patients
undergoing Primary Percutaneous Coronary Intervention)
trial. This trial has recently started recruitment and aims to
recruit 2000 participants in total across multiple sites to
assess whether rIC at the time of PPCI for STEMI can
reduce the combined primary outcome of cardiac death and
hospitalisation for heart failure at 12 months (https://clin
icaltrials.gov/ct2/show/NCT02342522).
DANAMI-3 (DANish Study of Optimal Acute Treat-
ment of Patients with ST-elevation Myocardial Infarction)
aims to assess the effect of local ischaemic conditioning on
heart failure rates up to 3 years following PPCI for STEMI
(http://clinicaltrials.gov/show/NCT01435408). The study
has completed recruitment of over 2000 participants, and
preliminary results pertaining to acute outcomes have
previously been presented [61]. RECOND (Reduction in
Infarct Size by Remote Per-postconditioning in Patients
With ST-elevation Myocardial Infarction), a Swedish-led
study, aims to recruit 120 participants and apply remote
per-conditioning during PPCI for STEMI. One of the aims
of the study is to compare cMRI-assessed remodelling
parameters after 180 days between the conditioned and
sham groups (https://clinicaltrials.gov/ct2/show/
NCT02021760). Finally, the RIC-STEMI trial (Remote
Ischaemic Conditioning in ST-elevation Myocardial
Infarction as Adjuvant to Primary Angioplasty) is a Por-
tuguese-led study aiming to recruit 492 participants. Sim-
ilarly, this study will recruit from patients suffering STEMI
and undergoing PPCI with a 1:1 randomisation to rIC
approximately 10 min prior to first angiographic balloon
inflation or sham conditioning. Rather than cMRI-based
outcomes, the primary endpoint in this study will be death
or hospitalisation from heart failure at a minimum of 1 year
(https://clinicaltrials.gov/ct2/show/NCT02313961).
Two phase II trials are underway with the hypothesis
that chronic, repeated rIC use in the post-STEMI period
can positively influence cardiac remodelling and reduce
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the incidence of and progression to heart failure: DREAM
(Daily REmote Conditioning in Acute Myocardial
Infarction) (http://clinicaltrials.gov/show/NCT01664611)
and CRIC (Chronic Remote Ischaemic Conditioning to
Modify Post-MI Remodelling) (http://clinicaltrials.gov/
show/NCT01817114). The DREAM study is a UK-based,
multi-centre randomised control trial recruiting individu-
als who have suffered a STEMI and have had successful
PPCI. Inclusion criteria includes post-STEMI LVEF
\45 % on transthoracic echocardiography with no prior
history of MI. The study aims to recruit 72 patients and is
powered to detect a 5 % increase in LVEF above natural
recovery. Primary outcome data are obtained from base-
line and 4-month cMRI to assess LVEF, left ventricular
end diastolic volume and systolic volume, infarct size and
oedema. An important facet of this trial is the intention to
try and elucidate further our understanding of how much
rIC in this context acts independently on remodelling
when influences on the initial infarct size and MVO
attenuation are reduced. This is done by beginning rIC
3 days after the acute event to avoid influencing the size
of the infarct. RIC will continue for 4 weeks, performed
daily by the participant. The study will randomise par-
ticipants 50:50 in the intervention or the control group.
The intervention group will receive a device that inflates
to 200 mmHg in 4 9 5-min cycles of inflation and
deflation. The control group will receive identical-looking
devices that cycle as the intervention group but only
inflate to a maximum of 10 mmHg. As conditioning
commences on day 3 post-MI, a greater focus is on the
modulation of the remodelling process rather than the
infarct sparing properties of rIC.
In a similar vein, the CRIC study is a multi-centre
randomised controlled trial recruiting from a STEMI/PPCI
population in Canada with a recruitment aim of 82. CRIC
differs from DREAM in that the investigators will recruit
left anterior descending (LAD) territory infarcts only and
will exclude diabetic individuals. The reasons for focusing
on non-diabetic patients who have suffered large anterior
STEMIs in the CRIC study are based on prior work, sug-
gesting that this group is most likely to respond to rIC and
hence gains greater impact from the intervention [1, 62,
63]. Furthermore, rIC will start just prior to PPCI and
continue for 4 weeks; therefore, rIC in this context will
likely have an influence on infarct size and MVO as well as
subsequent remodelling. Primary outcome will be obtained
by comparing cMRI at baseline and 28 days, primarily to
compare LVEDV. Both the DREAM and CRIC trials are
nearing completion, and it is hoped that once these trials
are completed we will be in a better position to assess the
role of chronic rIC in remodelling and whether this tech-
nique merits investigation with larger phase III randomised
control trials.
Challenges of remote ischaemic conditioning
The recent high-profile ERICCA trial, which showed no clin-
ical outcome benefit at 1 year when using rIC compared to
sham conditioning during elective on-pump CABG surgery,
has tempered the enthusiasm in some quarters for rIC as a
potential new cardioprotective therapy [64]. Pertaining to
cardioprotection in the context of MI and remodelling, a
number of key obstacles remain in effectively translating the
protection affordedby rIC in animal andearly clinical trials into
larger clinical trials andultimately into routine clinical practice.
One major challenge is that of timing of rIC. Patients
having an MI presenting late to centres that can administer
rIC may have completed their infarct and as such will
derive minimal benefit from the procedure with regard to
limiting I/R injury, although they may derive benefits from
remodelling [65]. Similarly, patients presenting with small
infarcts or those receiving PPCI or thrombolysis very early
may derive little benefit from rIC as the scope for addi-
tional cardioprotection in this setting is limited [66, 67].
Another significant challenge is that of the large comor-
bidities and polypharmacy that is often encountered in theMI
patient population. In particular type 2 diabetes, hyperlipi-
daemia, obesity and hypertension have all been shown to
increase the threshold required for effective rIC [68]. Con-
versely, a number of themedications used in the context ofMI
or commonly taken by this group of patients already provide a
significant degree of cardioprotection, namely ace inhibitors,
statins, opioids, insulin and a number of oral hypoglycaemic
agents including metformin [69]. There are also a few medi-
cation that can inhibit the effects of rIC including sulfony-
lureas [70]. These issues muddy the waters and make trial
design and subsequent clinical translation challenging.
Finally, from a practical perspective, because rIC
involves the application of a device on the arm that
requires a number of inflation and deflation cycles, even
with the use of an automated device, this can pose logis-
tical problems in the ambulance or the catheter laboratory
during PPCI where time is of the essence and gaining
arterial and venous access with the cuff in situ may pose an
issue. Furthermore, in scenarios, where rIC must be
administered on a regular basis by the patient to target
remodelling post-MI, the authors foresee significant con-
cordance issues which may limit the therapy in this con-
text. The use of automated rIC devices that can be
interrogated may go some way to overcomeing this issue.
Conclusions
RIC is only now beginning to reach its translational
potential with regard to protection from ischaemic/reper-
fusion injury. Long-term outcome data for one-off rIC at
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the time of MI are awaited from the CONDI-2, ERIC-
PPCI, DANAMI-3, RECOND and RIC-STEMI trials to
supplement promising results from smaller preliminary
studies. It is yet to be established whether early preclinical
data suggesting a clinically useful role for chronic, repe-
ated rIC use in the context of post-MI remodelling will be
borne out in the trial data, but it is hoped that results from
both the DREAM and CRIC trials will go some way to
answering this question and potentially open the door for
larger clinical trials to follow.
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